Hosted on MSN

PepGen Shares Skyrocket After Record DM1 Splicing Correction Results

PepGen Inc. (NASDAQ:PEPG) shares surged 145% following the biotech firm’s announcement of unprecedented splicing correction in patients with myotonic dystrophy type 1 (DM1) from its FREEDOM-DM1 Phase ...
Seeking Alpha

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

– Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – PGN-EDODM1 observed to have favorable emerging safety profile – – Conference call scheduled today ...
Morningstar

PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data

– Mean splicing correction of 7.3% observed with PGN-EDODM1 (n=6) versus 6.8% with placebo (n=2); Excluding one outlier patient, treatment group demonstrated mean splicing correction of 22.9% (n=5) – ...
Seeking Alpha

PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data Transcript

Welcome to the PepGen conference call to discuss top line results from lowest dose MAD cohort in the Phase II FREEDOM2 study, demonstrating promising safety, splicing and vHOT data. [Operator ...